Friday, April 4, 2025
4/4/2025
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells - In this renewal R01A1 application (parent R01CA240290; “Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells”), we continue to develop novel strategies to tackle a pervasive and intertwined problem of clinical significance in PCa, i.e., PCa cell heterogeneity and plasticity. PCa continues to claim a high mortality with >35,000 American men estimated to die from metastatic castration-resistant PCa (mCRPC) in 2024. This high mortality and increased diagnosis of advanced PCa have been linked to PCa cell heterogeneity (e.g., in androgen receptor; AR) and treatment- induced plasticity. It has become clear that the entire spectrum of primary PCa, CRPC and metastases harbors not only AR-expressing (AR+) cells but also a population of PCa cells with little/no AR (AR-/lo), the latter of which often become expanded in mCRPC. Clinically, since introduction of the new generation of antiandrogens such as enzalutamide (Enza), there has been a dramatic increase (up to 20-40%) in AR-/lo mCRPC. Compared to AR+ cells, the AR-/lo PCa cells are understudied and poorly understood. Our focused work over the past 22 years has advanced our understanding of AR-/lo PCa cells and the dynamic relationship between AR-/lo and AR+ cells in PCa ecosystem and during PCa progression. For example, we have demonstrated that the AR-/lo PCa cell population in treatment-naïve tumors harbors PCa stem cells (PCSCs), and we have identified novel targets in AR-/lo PCa cells that have been translated to clinical trials (e.g., NCT03751436). Herein, we have made new and unexpected findings that AR-/lo PCa cells preferentially express genes involved in homologous recombination (HR) based DNA damage response/repair (DDR) including ATR, ATM and BRCA2. Remarkably, many of the same HR genes are also highly expressed in AR-/lo genetically engineered mouse models (GEMMs) of PCa (Pten-/-;Rb1-/-; DKO and Pten-/-Rb1-/-p53-/-; TKO) as well as in patient AR- mCRPC that have undergone Enza-induced plasticity. In contrast, AR+ PCa cells mainly express PARP1 and NHEJ genes and utilize NHEJ for DDR. These exciting preliminary data led us to hypothesize that the AR-/lo PCa cells primarily employ the HR pathway to repair the DNA damage which makes these cells highly vulnerable to HR pathway inhibition. Therefore, combination of ATR inhibitor (ATRi) and ADT/Enza will elicit synthetic lethality and represents a novel therapeutic regimen to holistically target both AR-/lo and AR+ PCa cells. We test this hypothesis with 3 Aims: Aim 1: Test in PCa GEMMs that ATRi combined with castration/Enza will inhibit CRPC and ATRi alone will be highly effective against AR-lo CRPC/NEPC; Aim 2: Evaluate the therapeutic effects of ATRi alone on AR-/lo and ATRi/Enza combination on AR+ human CRPC/PDX models; and Aim 3: Define the DDR pathway dynamics and functions in AR+ and AR-/lo PCa cells using cell line and organoid models as well as patient tumor samples. These aims will be accomplished by therapeutic studies in the DKO/TKO GEMMs and human xenograft/PDX/organoid models combined with mechanistic investigations.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).